Zeneca breaks into UK with Casodex launch
05 August 1995 00:00 [Source: ICB]
ZENECA HAS launched a treatment for advanced prostate cancer in its first market, the UK. The drug, Casodex, an oral anti-androgen, is licensed for use in combination with a luteinizing hormone releasing hormone analogue, such as Zeneca's Zoladex, or surgical castration.
The 1994 UK anti-androgen market was valued at £15m ($24m). Zeneca won UK marketing approval for Casodex late February, followed by approval in Ireland in April.
The company said in the UK half the 14 000 patients/year diagnosed with prostate cancer have advanced disease, and more than two-thirds of prostate cancers are hormone dependent and likely to respond to anti-androgens used in combination therapy.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|
Subscribe Today Sample issue >> My Account/Renew >> Register for online access >> |
| ICIS Top 100 Chemical Companies |
|
|
Related Articles
- 18 Mar 99 10:12 Zeneca wins approval in Japan for 'Casodex'
Latest News
- 21 May 13 23:46 April US BD production falls by 8.4% in April from March, Petral
- 21 May 13 23:45 US KBR to provide FEED for LNG export facility in BC, Canada
- 21 May 13 23:30 PVC demand declines in Argentina on lack of government projects
- 21 May 13 23:06 Brazil PVC demand expected to grow up to 6% by year end
- 21 May 13 23:00 EVENING SNAPSHOT - Americas Markets Summary